Literature DB >> 11849633

Assessment of compliance with a weekly contraceptive patch (Ortho Evra/Evra) among North American women.

David F Archer1, Alison Bigrigg, Geoffrey H Smallwood, Gary A Shangold, George W Creasy, Alan C Fisher.   

Abstract

OBJECTIVE: To determine compliance with the contraceptive patch (Ortho Evra/Evra) overall and by age among women in North America and to compare rates of perfect use with those of an established oral contraceptive.
DESIGN: Data were pooled for three contraceptive studies in which women participated for up to 13 cycles; the subset of centers in North America was used in this analysis.
SETTING: 76 North American centers. PATIENT(S): Healthy women 18-45 years of age. INTERVENTION(S): In all studies, the patch regimen was three consecutive 7-day patches (21 days) followed by 1 patch-free week per cycle. MAIN OUTCOME MEASURE(S): Perfect use for the patch or oral contraceptive, defined as 21 consecutive days of drug-taking followed by a 7-day drug-free period; for contraceptive patch users, no patch could be worn for more than 7 days. Oral contraceptives were used according to package labeling.
RESULTS: For all contraceptive patch users in North America (n = 1,785), perfect use was consistent across age groups. The percentage of cycles with perfect use of the patch ranged within age groups from 88.1% to 91.0%. In the comparative study conducted only in North America, perfect use was also consistent across age groups for the patch (n = 812), but rates of perfect use for the oral contraceptive (n = 605) differed significantly by age. CONCLUSION(S): Age did not affect compliance with the patch among all North American women studied. In a comparative study of women at North American centers, compliance with the weekly contraceptive patch was significantly better than with an established oral contraceptive. The contraceptive patch is uniformly easy to use across all ages.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11849633     DOI: 10.1016/s0015-0282(01)03263-0

Source DB:  PubMed          Journal:  Fertil Steril        ISSN: 0015-0282            Impact factor:   7.329


  11 in total

1.  Transdermal therapy for overactive bladder: present and future.

Authors:  Victor W Nitti
Journal:  Rev Urol       Date:  2003

2.  One-year contraceptive continuation and pregnancy in adolescent girls and women initiating hormonal contraceptives.

Authors:  Tina R Raine; Anne Foster-Rosales; Ushma D Upadhyay; Cherrie B Boyer; Beth A Brown; Abby Sokoloff; Cynthia C Harper
Journal:  Obstet Gynecol       Date:  2011-02       Impact factor: 7.661

Review 3.  Hormonal contraception in adolescents: special considerations.

Authors:  Rollyn M Ornstein; Martin M Fisher
Journal:  Paediatr Drugs       Date:  2006       Impact factor: 3.022

Review 4.  Skin patch and vaginal ring versus combined oral contraceptives for contraception.

Authors:  Laureen M Lopez; David A Grimes; Maria F Gallo; Laurie L Stockton; Kenneth F Schulz
Journal:  Cochrane Database Syst Rev       Date:  2013-04-30

5.  High levels of women's satisfaction and compliance with transdermal contraception: results from a European multinational, 6-month study.

Authors:  A J Jakimiuk; P G Crosignani; T Chernev; V Prilepskaya; P Bergmans; M Von Poncet; S Marelli; E J Lee
Journal:  Gynecol Endocrinol       Date:  2010-12-10       Impact factor: 2.260

6.  Satisfaction and compliance in hormonal contraception: the result of a multicentre clinical study on women's experience with the ethinylestradiol/norelgestromin contraceptive patch in Italy.

Authors:  Pier Giorgio Crosignani; Carmine Nappi; Salvatore Ronsini; Vincenzina Bruni; Silvia Marelli; Davide Sonnino
Journal:  BMC Womens Health       Date:  2009-06-30       Impact factor: 2.809

Review 7.  Transdermal delivery of combined hormonal contraception: a review of the current literature.

Authors:  Rosanna M Galzote; Sally Rafie; Rachel Teal; Sheila K Mody
Journal:  Int J Womens Health       Date:  2017-05-15

8.  Safety, efficacy and patient acceptability of the combined estrogen and progestin transdermal contraceptive patch: a review.

Authors:  Alessandra Graziottin
Journal:  Patient Prefer Adherence       Date:  2008-02-02       Impact factor: 2.711

9.  Mathematical modeling of the release of active ingredients from a contraceptive patch: ortho evra(®) as a case study.

Authors:  Grissel Trujillo-de Santiago; Carlos Patricio Sáenz-Collins; Lizette García-Arellano; Mario Moisés Álvarez
Journal:  Iran J Pharm Res       Date:  2014       Impact factor: 1.696

10.  Evaluation of factors associated with noncompliance in users of combined hormonal contraceptive methods: a cross-sectional study: results from the MIA study.

Authors:  Txantón Martínez-Astorquiza-Ortiz de Zarate; Teresa Díaz-Martín; Txantón Martínez-Astorquiza-Corral
Journal:  BMC Womens Health       Date:  2013-10-20       Impact factor: 2.809

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.